The Food and Drug Administration is looking into whether three possible health issues or side effects, including hair loss and thoughts of suicide, might be linked to a group of medications that have boomed in popularity for their use in weight loss, including Ozempic, Wegovy, Mounjaro and Zepbound.

The probe into these issues was disclosed Tuesday in a quarterly report by the FDA, which revealed that the agency is investigating reports of alopecia, a hair loss condition; aspiration, a complication during surgery when people inhale food or other objects into their airway; and suicidal ideation in people who used the medications.

…

While issues investigated by the agency sometimes turn out to be little more than false alarms, the agency’s previous probes of reported side effects have also often led to the FDA updating a drug’s labels or precautions, or calling for additional study of the issue.